Next Generation Immune Checkpoint Inhibitors Market (2nd Edition), by Target Immune Checkpoint, Target Disease Indication, Type of Molecule, Geographical Regions, Leading Players and Sales Forecast of Therapies - Trends and Forecast Till 2035

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Developers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis ofInflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5.1. Immune Checkpoint Inhibitors: Market Landscape
5.2. Immune Checkpoint Inhibitors: Market Trends
5.3. Immune Checkpoint Inhibitors: Market Forecast and Opportunity Analysis

6.1. Chapter Overview
6.2. Introduction to Cancer Immunotherapy
6.3. Fundamentals of Cancer Immunotherapy
6.4. Immune Checkpoint Inhibitors
6.5. First Generation Immune Checkpoint Modulators
6.6. Next Generation Immune Checkpoint Modulators
6.6.1. Types of Next Generation Modulators
6.7. Challenges Related to Immune Checkpoint Inhibitors
6.8. Future Perspective

7.1. Chapter Overview
7.2. Immune Checkpoint Inhibitors: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Target Immune Checkpoint
7.2.3. Analysis by Therapeutic Modality
7.2.4. Analysis by Route of Administration
7.2.5. Analysis by Target Disease Indication
7.2.6. Analysis by Therapeutic Area
7.2.7. Analysis by Popular Oncological Indications and Target Immune Checkpoints
7.2.8. Analysis by Popular Non-Oncological Indications and Target Immune Checkpoints
7.3. Immune Checkpoint Inhibitors: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Most Active Players: Analysis by Number of Immune Checkpoint Inhibitors Developed
7.3.6. Prominent First Generation Targets: Distribution by Number of Developers

8.1. Chapter Overview
8.2. Next Generation Immune Checkpoint Inhibitors: Overall Market Landscape
8.2.1. Analysis by Stage of Development
8.2.2. Analysis by Target Immune Checkpoint
8.2.3. Analysis by Therapeutic Modality
8.2.4. Analysis by Route of Administration
8.2.5. Analysis by Target Disease Indication
8.2.6. Analysis by Therapeutic Area
8.2.7. Analysis by Popular Oncological Indications and Popular Target Immune Checkpoint
8.2.8. Analysis by Popular Non-Oncological Indications and Target Immune Checkpoint
8.3. Next Generation Immune Checkpoint Inhibitors: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Analysis by Company Size and Location of Headquarters
8.3.5. Most Active Players: Analysis by Number of Immune Checkpoint Inhibitors Developed
8.3.6. Prominent Next Generation Targets: Distribution by Number of Developers

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Key Parameters
9.4. Target Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors
9.4.1. Target Competitiveness Analysis: 3D Bubble Analysis
9.4.2. Target Competitiveness Analysis: Spider Web Analysis

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Immune Checkpoint Inhibitors: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Registration Year and Trial Status
10.3.4. Analysis by Trial Registration Year and Patients Enrolled
10.3.5. Analysis by Trial Status and Patients Enrolled
10.3.6. Analysis by Trial Phase
10.3.7. Analysis by Patients Enrolled and Trial Phase
10.3.8. Analysis by Study Design
10.3.9. Analysis by Type of Sponsor
10.3.10. Analysis by Patient Gender
10.3.11. Most Active Industry Players: Analysis by Number of Trials
10.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
10.3.13. Analysis by Geography
10.3.13.1. Analysis by Trial Status, Trial Phase and Geography
10.3.13.2. Analysis by Trial Status and Geography
10.3.14. Geographical Distribution of Trials and Number of Patients Enrolled

11.1. Chapter Overview
11.2. Immune Checkpoint Inhibitors Offered by Drug Developers Based in North America
11.2.1. Arcus
11.2.1.1. Company Overview
11.2.1.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.2.1.2.1. Domvanalimab
11.2.1.2.2. Quemliclustat
11.2.1.3. Recent Developments and Future Outlook
11.2.2. Genentech
11.2.2.1. Company Overview
11.2.2.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.2.2.2.1. Tiragolumab
11.2.2.3. Recent Developments and Future Outlook
11.2.3. Johnson & Johnson
11.2.3.1. Company Overview
11.2.3.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.2.3.2.1. Daratumumab
11.2.3.3. Recent Developments and Future Outlook
11.2.4. Merck
11.2.4.1. Company Overview
11.2.4.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.2.4.2.1. Ifinatamab Deruxtecan
11.2.4.3. Recent Developments and Future Outlook
11.2.5. NovaBridge Biosciences
11.2.5.1. Company Overview
11.2.5.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.2.5.2.1. Uliledlimab
11.2.5.3. Recent Developments and Future Outlook
11.2.6. Regeneron Pharmaceuticals
11.2.6.1. Company Overview
11.2.6.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.2.6.2.1. FIANLIMAB
11.2.6.3. Recent Developments and Future Outlook
11.3. Immune Checkpoint Inhibitors Offered by Drug Developers Based in Europe
11.3.1. GlaxoSmithKline
11.3.1.1. Company Overview
11.3.1.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.3.1.2.1. GSK5764227
11.3.1.2.2. GSK5733584
11.3.1.3. Recent Developments and Future Outlook
11.3.2. Sanofi
11.3.2.1. Company Overview
11.3.2.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.3.2.2.1. Sarclisa
11.3.2.3. Recent Developments and Future Outlook
11.4. Immune Checkpoint Inhibitors Offered by Drug Developers Based in Asia-Pacific
11.4.1. Aurigene Oncology
11.4.1.1. Company Overview
11.4.1.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.4.1.2.1. Cenopodlin
11.4.1.3. Recent Developments and Future Outlook
11.4.2. Ono Pharmaceutical
11.4.2.1. Company Overview
11.4.2.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.4.2.2.1. ONO-4482
11.4.2.3. Recent Developments and Future Outlook
11.4.3. Takeda Pharmaceutical
11.4.3.1. Company Overview
11.4.3.2. Next Generation Immune Checkpoint Therapeutics Portfolio
11.4.3.2.1. Mezagitamab
11.4.3.3. Recent Developments and Future Outlook

12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Next Generation Immune Checkpoint Inhibitors Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
13.4. Multivariate Scenario Analysis
13.4.1. Conservative Scenario
13.4.2. Optimistic Scenario
13.5. Key Market Segmentations

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Immune Checkpoint
14.3.1. Next Generation Immune Checkpoint Inhibitors Market for CD38, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.2. Next Generation Immune Checkpoint Inhibitors Market for B7-H3, Forecasted Estimates (till 2035)
14.3.3. Next Generation Immune Checkpoint Inhibitors Market for TIGIT, Forecasted Estimates (till 2035)
14.3.4. Next Generation Immune Checkpoint Inhibitors Market for LAG-3, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.5. Next Generation Immune Checkpoint Inhibitors Market for CD73, Forecasted Estimates (till 2035)
14.4. Data Triangulation and Validation

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Disease Indications
15.3.1. Next Generation Immune Checkpoint Inhibitors Market for Multiple Myeloma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.3.2. Next Generation Immune Checkpoint Inhibitors Market for Lung Cancer, Forecasted Estimates (Till 2035)
15.3.3. Next Generation Immune Checkpoint Inhibitors Market for Immune Thrombocytopenia, Forecasted Estimates (Till 2035)
15.3.4. Next Generation Immune Checkpoint Inhibitors Market for Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.3.4. Next Generation Immune Checkpoint Inhibitors Market for Prostate Cancer, Forecasted Estimates (Till 2035)
15.3.6. Next Generation Immune Checkpoint Inhibitors Market for Esophageal Cancer, Forecasted Estimates (Till 2035)
15.3.7. Next Generation Immune Checkpoint Inhibitors Market for Light Chain Amyloidosis, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.3.8. Next Generation Immune Checkpoint Inhibitors Market for Pancreatic Cancer, Forecasted Estimates (Till 2035)
15.4. Data Triangulation and Validation

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Type of Molecule
16.3.1. Next Generation Immune Checkpoint Inhibitors Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.3.2. Next Generation Immune Checkpoint Inhibitors Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.4. Data Triangulation and Validation

17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Geographical Regions
17.3.1. Next Generation Immune Checkpoint Inhibitors Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.1.1. Next Generation Immune Checkpoint Inhibitors Market in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.1.2. Next Generation Immune Checkpoint Inhibitors Market in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.2. Next Generation Immune Checkpoint Inhibitors Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.2.1. Next Generation Immune Checkpoint Inhibitors Market in EU5, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.2.2. Next Generation Immune Checkpoint Inhibitors Market in the Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3. Next Generation Immune Checkpoint Inhibitors Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.1. Next Generation Immune Checkpoint Inhibitors Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.2. Next Generation Immune Checkpoint Inhibitors Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.3. Next Generation Immune Checkpoint Inhibitors Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.4. Next Generation Immune Checkpoint Inhibitors Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.5. Next Generation Immune Checkpoint Inhibitors Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.6. Next Generation Immune Checkpoint Inhibitors Market in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.7. Next Generation Immune Checkpoint Inhibitors Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.8. Next Generation Immune Checkpoint Inhibitors Market in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3.9. Next Generation Immune Checkpoint Inhibitors Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Leading Players
18.3.1. Next Generation Immune Checkpoint Inhibitors Market for Arcus Biosciences, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.2. Next Generation Immune Checkpoint Inhibitors Market for Daiichi Sankyo, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.3. Next Generation Immune Checkpoint Inhibitors Market for GlaxoSmithKline, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.4. Next Generation Immune Checkpoint Inhibitors Market for Johnson and Johnson, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.5. Next Generation Immune Checkpoint Inhibitors Market for ONO Pharmaceuticals, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.6. Next Generation Immune Checkpoint Inhibitors Market for Regeneron Pharmaceuticals, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.7. Next Generation Immune Checkpoint Inhibitors Market for Sanofi, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.8. Next Generation Immune Checkpoint Inhibitors Market for Takeda, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Next Generation Immune Checkpoint Inhibitors Market: Sales Forecast of Therapies
19.3.1. Darzalex: Sales Forecast (USD Million)
19.3.2. Sarclisa: Sales Forecast (USD Million)
19.3.3. ONO-4482: Sales Forecast (USD Million)
19.3.4. Ifinatamab Deruxtecan / MK-2400: Sales Forecast (USD Million)
19.3.5. GSK5764227: Sales Forecast (USD Million)
19.3.6. Mezagitamab (TAK-079): Sales Forecast (USD Million)
19.3.7. Fianlimab: Sales Forecast (USD Million)
19.3.8. Quemliclustat: Sales Forecast (USD Million)
19.3.9. Domvanalimab: Sales Forecast (USD Million)
19.4. Data Triangulation and Validation

21.1. Chapter Overview
21.2. Percheron Therapeutics
21.2.1 Company Snapshot
21.2.2. Interview Transcript: James Garner (Chief Executive Officer)
21.3. Merck
21.3.1 Company Snapshot
21.3.2. Interview Transcript: Rob Davis (Chief Executive Officer)

Table 6.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 6.2 First Generation Immune Checkpoint Therapies
Table 7.1 Immune Checkpoint Inhibitors: Information on Developer, Drug Name, Target, Generation of Immune Checkpoint Inhibitor and Stage of Development
Table 7.2 Immune Checkpoint Inhibitors: Information on Drug Name, Type of Molecule and Route of Administration
Table 7.3 Immune Checkpoint Inhibitors: Information on Target Indication, Therapeutic Area and Type of Therapy
Table 7.4 Immune Checkpoint Inhibitors: Information on Drug Designations
Table 7.5 Immune Checkpoint Inhibitors Developers: Information on Year of Establishment, Location of Headquarters (Country / Region) and Company Size
Table 8.1 Next Generation Immune Checkpoint Inhibitors: Information on Developer, Drug Name, Target, Generation of Immune Checkpoint Inhibitor and Stage of Development
Table 8.2 Next Generation Immune Checkpoint Inhibitors: Information on Drug Name, Type of Molecule and Route of Administration
Table 8.3 Next Generation Immune Checkpoint Inhibitors: Information on Target Indication, Therapeutic Area and Type of Therapy
Table 8.4 Next Generation Immune Checkpoint Inhibitors: Information on Drug Designations
Table 8.5 Next Generation Immune Checkpoint Inhibitors Developers: Information on Year of Establishment, Location of Headquarters (Country / Region) and Company Size
Table 8.5 Next Generation Immune Checkpoint Inhibitors Developers: Information on Year of Establishment, Location of Headquarters (Country / Region) and Company Size
Table 11.1 Next Generation Immune Checkpoint Inhibitors: List of Drug Developers Profiled
Table 11.2 Arcus Biosciences: Company Overview
Table 11.3 Drug Profile: Domvanalimab
Table 11.4 Drug Profile: Quemliclustat
Table 11.5 Arcus Biosciences: Recent Developments and Future Outlook
Table 11.6 Genentech: Company Overview
Table 11.7 Drug Profile: Tiragolumab
Table 11.8 Johnson & Johnson: Company Overview
Table 11.9 Drug Profile: Daratumumab
Table 11.10 Johnson & Johnson: Recent Developments and Future Outlook
Table 11.11 Merck: Company Overview
Table 11.12 Drug Profile: Ifinatamab Deruxtecan
Table 11.13 Merck: Recent Developments and Future Outlook
Table 11.14 NovaBridge Biosciences: Company Overview
Table 11.15 Drug Profile: Uliledlimab
Table 11.16 NovaBridge Biosciences: Recent Developments and Future Outlook
Table 11.17 Regeneron Pharmaceuticals: Company Overview
Table 11.18 Drug Profile: FIANLIMAB
Table 11.19 Regeneron Pharmaceuticals: Recent Developments and Future Outlook
Table11.20 Glaxosmithkline: Company Overview
Table11.21 Drug Profile: GSK5764227
Table11.22 Drug Profile: GSK5733584
Table11.23 Glaxosmithkline: Recent Developments and Future Outlook
Table11.24 Sanofi: Company Overview
Table11.25 Drug Profile: Sarclisa
Table11.26 Sanofi: Recent Developments and Future Outlook
Table11.27 Aurigene Oncology: Company Overview
Table11.28 Drug Profile: Cenopodlin
Table11.29 Ono Pharmaceutical: Company Overview
Table11.30 Drug Profile: ONO-4482
Table11.31 Takeda Pharmaceutical: Company Overview
Table11.32 Drug Profile: Mezagitamab
Table 13.1 Next Generation Immune Checkpoint Inhibitors: List of Forecasted Therapies
Table 22.1 Immune Checkpoint Inhibitors: Distribution by Generation of Target Immune Checkpoint
Table 22.2 Immune Checkpoint Inhibitors: Distribution by Stage of Development
Table 22.3 Immune Checkpoint Inhibitors: Analysis Type of Molecule
Table 22.4 Immune Checkpoint Inhibitors: Distribution by Route of Administration
Table 22.5 Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
Table 22.6 Immune Checkpoint Inhibitors: Analysis of Prominent Oncological Indications
Table 22.7 Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
Table 22.8 Immune Checkpoint Inhibitors: Distribution by Type of Therapy
Table 22.9 Immune Checkpoint Inhibitors: Distribution by Drug Designations
Table 22.10 Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
Table 22.11 Immune Checkpoint Inhibitor Developers: Distribution by Company Size
Table 22.12 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Region)
Table 22.13 Immune Checkpoint Inhibitor
Developers: Distribution by Location of Headquarters (Country)
Table 22.14 Most Active Players: Distribution by Number of Immune Checkpoint Inhibitor Therapies
Table 22.15 Most Active Players: Distribution by Prominent Targets
Table 22.16 Next Generation Immune Checkpoint Inhibitors: Distribution by Target Immune Checkpoint
Table 22.17 Next Generation Immune Checkpoint Inhibitors: Analysis Stage of Development
Table 22.18 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Table 22.19 Next Generation Immune Checkpoint Inhibitors: Distribution by Route of Administration
Table 22.20 Next Generation Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
Table 22.21 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Oncological Indications
Table 22.22 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
Table 22.23 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Therapy
Table 22.24 Next Generation Immune Checkpoint Inhibitors: Distribution by Drug Designations
Table 22.25 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
Table 22.26 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Company Size
Table 22.27 Next Generation Immune Checkpoint Inhibitor Developers; Distribution by Location of Headquarters (Region)
Table 22.28 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
Table 22.29 Most Active Players: Distribution by Number of Next Generation Immune Checkpoint Inhibitor Therapies
Table 22.30 Prominent Next Generation Targets: Distribution by Number of Developers
Table 22.31 Clinical Trial Analysis: Distribution by Trial Registration Year, Since Pre-2021
Table 22.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since Pre-2021
Table 22.33 Clinical Trial Analysis: Distribution by Trial Status
Table 22.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 22.35 Clinical Trial Analysis: Distribution by Trial Phase
Table 22.36 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 22.37 Clinical Trial Analysis: Distribution by Patient Gender
Table 22.38 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 22.39 Clinical Trial Analysis: Distribution by Type of Allocation
Table 22.40 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 22.41 Clinical Trial Analysis: Distribution by Type of Masking
Table 22.42 Clinical Trial Analysis: Distribution by Primary Purpose
Table 22.43 Clinical Trial Analysis:
Distribution by Type of Sponsor / Collaborator
Table 22.44 Most Active Industry Players: Distribution by Number of Registered Trials
Table 22.45 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 22.46 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 22.47 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 23.48 Global Next Generation Immune Checkpoint Inhibitors Market, Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Table 23.49 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till
2035): Conservative Scenario (USD Million)
Table 22.50 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 22.51 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Immune Checkpoint (USD Million)
Table 22.52 Next Generation Immune Checkpoint Inhibitors Market for CD38, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.53 Next Generation Immune Checkpoint Inhibitors Market for B7-H3, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.54 Next Generation Immune Checkpoint Inhibitors Market for TIGIT, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD
Million)
Table 22.55 Next Generation Immune Checkpoint Inhibitors Market for LAG-3, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.56 Next Generation Immune Checkpoint Inhibitors Market for CD73, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.57 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Disease Indication (USD Million)
Table 22.58 Next Generation Immune Checkpoint Inhibitors Market for Multiple Myeloma, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.59 Next Generation Immune Checkpoint Inhibitors Market for Lung Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.60 Next Generation Immune Checkpoint Inhibitors Market for Immune Thrombocytopenia, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.61 Next Generation Immune Checkpoint Inhibitors Market for Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.62 Next Generation Immune Checkpoint Inhibitors Market for Prostate Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.63 Next Generation Immune Checkpoint Inhibitors Market for Esophageal Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.64 Next Generation Immune Checkpoint Inhibitors Market for Light Chain Amyloidosis, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.65 Next Generation Immune Checkpoint Inhibitors Market for Pancreatic Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.66 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Type of Molecule (USD Million)
Table 22.67 Next Generation Immune Checkpoint Inhibitors Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.68 Next Generation Immune Checkpoint Inhibitors Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.69 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Geographical Regions (USD Million)
Table 22.70 Next Generation Immune Checkpoint Inhibitors Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.71 Next Generation Immune Checkpoint Inhibitors Market for the US, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.72 Next Generation Immune Checkpoint Inhibitors Market for Canada, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.71 Next Generation Immune Checkpoint Inhibitors Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.73 Next Generation Immune Checkpoint Inhibitors Market for EU5, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.74 Next Generation Immune Checkpoint Inhibitors Market for Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.75 Next Generation Immune Checkpoint Inhibitors Market for Asia-Pacific and Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.76 Next Generation Immune Checkpoint Inhibitors Market for China, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD
Million)
Table 22.77 Next Generation Immune Checkpoint Inhibitors Market for Japan, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.78 Next Generation Immune Checkpoint Inhibitors Market for Brazil, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD
Million)
Table 22.79 Next Generation Immune Checkpoint Inhibitors Market for Australia, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.80 Next Generation Immune Checkpoint Inhibitors Market for South Korea, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.81 Next Generation Immune Checkpoint Inhibitors Market for India, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.82 Next Generation Immune Checkpoint Inhibitors Market for Argentina, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.83 Next Generation Immune Checkpoint Inhibitors Market for Israel, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.84 Next Generation Immune Checkpoint Inhibitors Market for Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.85 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Leading Players (USD Million)
Table 22.86 Next Generation Immune Checkpoint Inhibitors Market for Johnson and Johnson, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.87 Next Generation Immune Checkpoint Inhibitors Market for Daichii Sankyo, Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.88 Next Generation Immune Checkpoint Inhibitors Market for Arcus Biosciences, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.89 Next Generation Immune Checkpoint Inhibitors Market for GlaxoSmithKline, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.90 Next Generation Immune Checkpoint Inhibitors Market for Takeda, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.91 Next Generation Immune Checkpoint Inhibitors Market for Sanofi, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.92 Next Generation Immune Checkpoint Inhibitors Market for Regeneron Pharmaceuticals, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.93 Next Generation Immune Checkpoint Inhibitors Market for ONO Pharmaceuticals, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and
Optimistic Scenarios (USD Million)
Table 22.94 Next Generation Immune Checkpoint Inhibitors Market: Sales Forecast for Therapies, 2022, 2026 and 2035 (USD Million)
Table 22.95 Next Generation Immune Checkpoint Inhibitors Market for Darzalex, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.96 Next Generation Immune Checkpoint Inhibitors Market for Sarclisa, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.97 Next Generation Immune Checkpoint Inhibitors Market for ONO-4882, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.98 Next Generation Immune Checkpoint Inhibitors Market for Ifinatamab Deruxtecan / MK-2400, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.99 Next Generation Immune Checkpoint Inhibitors Market for GSK5764227, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.100 Next Generation Immune Checkpoint Inhibitors Market for Mezagitamab (TAK-079), Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.101 Next Generation Immune Checkpoint Inhibitors Market for Fianlimab, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.102 Next Generation Immune Checkpoint Inhibitors Market for Quemliclustat, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 22.103 Next Generation Immune Checkpoint Inhibitors Market for Domvanalimab, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Global Age-Standardized Incidence Rates for Cancer in Top 5 Countries, 2025
Figure 6.2 Mechanisms of Immunotherapies
Figure 6.3 Immune Checkpoint Therapies
Figure 7.1 Immune Checkpoint Inhibitors: Distribution by Generation of Target Immune Checkpoint
Figure 7.2 Immune Checkpoint Inhibitors: Distribution by Stage of Development
Figure 7.3 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 7.4 Immune Checkpoint Inhibitors: Distribution by Route of Administration
Figure 7.5 Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
Figure 7.6 Immune Checkpoint Inhibitors: Distribution by Prominent Oncological Indications
Figure 7.7 Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
Figure 7.8 Immune Checkpoint Inhibitors: Distribution by Type of Therapy
Figure 7.9 Immune Checkpoint Inhibitors: Distribution by Drug Designations
Figure 7.10 Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
Figure 7.11 Immune Checkpoint Inhibitor Developers: Distribution by Company Size
Figure 7.12 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Region)
Figure 7.13 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
Figure 7.14 Most Active Players: Distribution by Number of Immune Checkpoint Inhibitor Therapies Developed
Figure 7.15 Prominent Targets: Distribution by Number of Developers
Figure 8.1 Next Generation Immune Checkpoint Inhibitors: Distribution by Target Immune Checkpoint
Figure 8.2 Next Generation Immune Checkpoint Inhibitors: Distribution by Stage of Development
Figure 8.3 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 8.4 Next Generation Immune Checkpoint Inhibitors: Distribution by Route of Administration
Figure 8.5 Next Generation Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
Figure 8.6 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Oncological Indications
Figure 8.7 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
Figure 8.8 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Therapy
Figure 8.9 Next Generation Immune Checkpoint Inhibitors: Distribution Drug Designations
Figure 8.10 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
Figure 8.11 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Company Size
Figure 8.12 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Region)
Figure 8.13 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
Figure 8.14 Most Active Players: Distribution by Number of Next Generation Immune Checkpoint Inhibitor Therapies Developed
Figure 8.15 Prominent Next Generation Targets: Distribution by Number of Developers
Figure 9.1 Target Competitiveness Analysis: 3D Bubble Analysis for Next Generation Immune Checkpoint Inhibitor Targets
Figure 9.2 Next Generation Immune Checkpoint Therapies: Spider Web Analysis
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since Pre-2021
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since Pre-2021
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 10.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.8 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.9 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 10.11 Clinical Trial Analysis: Distribution by Type of Masking
Figure 10.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 10.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.14 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 10.15 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 10.16 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.17 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 10.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 13.1 Global Next Generation Immune Checkpoint Inhibitors Market, Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 13.2 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 13.3 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 14.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Immune Checkpoint
Figure 14.2 Next Generation Immune Checkpoint Inhibitors Market for CD38: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 14.3 Next Generation Immune Checkpoint Inhibitors Market for B7-H3: Forecasted Estimates (till 2035) (USD Million)
Figure 14.4 Next Generation Immune Checkpoint Inhibitors Market for TIGIT: Forecasted Estimates (till 2035) (USD Million)
Figure 14.5 Next Generation Immune Checkpoint Inhibitors Market for LAG-3: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 14.6 Next Generation Immune Checkpoint Inhibitors Market for CD73: Forecasted Estimates (till 2035) (USD Million)
Figure 15.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Disease Indication
Figure 15.2 Next Generation Immune Checkpoint Inhibitors Market for Multiple Myeloma: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 15.3 Next Generation Immune Checkpoint Inhibitors Market for Lung Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 15.4 Next Generation Immune Checkpoint Inhibitors Market for Immune Thrombocytopenia: Forecasted Estimates (till 2035) (USD Million)
Figure 15.5 Next Generation Immune Checkpoint Inhibitors Market for Melanoma: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 15.6 Next Generation Immune Checkpoint Inhibitors Market for Prostate Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 15.7 Next Generation Immune Checkpoint Inhibitors Market for Esophageal Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 15.8 Next Generation Immune Checkpoint Inhibitors Market for Light Chain Amyloidosis: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 15.9 Next Generation Immune Checkpoint Inhibitors Market for Pancreatic Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 16.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Type of Molecule
Figure 16.2 Next Generation Immune Checkpoint Inhibitors Market for Biologics: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 16.3 Next Generation Immune Checkpoint Inhibitors Market for Small Molecules: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Geographical Regions
Figure 17.2 Next Generation Immune Checkpoint Inhibitors Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.3 Next Generation Immune Checkpoint Inhibitors Market in United States: Historical Trends (Since 2022) and Forecasted Estimates (till
2035) (USD Million)
Figure 17.4 Next Generation Immune Checkpoint Inhibitors Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.5 Next Generation Immune Checkpoint Inhibitors Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.6 Next Generation Immune Checkpoint Inhibitors Market in EU5: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.7 Next Generation Immune Checkpoint Inhibitors Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.8 Next Generation Immune Checkpoint Inhibitors Market in Asia-Pacific and Rest of the World: Historical trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.9 Next Generation Immune Checkpoint Inhibitors Market in China: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.10 Next Generation Immune Checkpoint Inhibitors Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.11 Next Generation Immune Checkpoint Inhibitors Market in Brazil: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.12 Next Generation Immune Checkpoint Inhibitors Market in Australia: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.13 Next Generation Immune Checkpoint Inhibitors Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.14 Next Generation Immune Checkpoint Inhibitors Market in India: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.15 Next Generation Immune Checkpoint Inhibitors Market in Aregntina: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.16 Next Generation Immune Checkpoint Inhibitors Market in Israel: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.17 Next Generation Immune Checkpoint Inhibitors Market in Saudi Arabia: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Sales Forecast of Leading Players
Figure 18.2 Next Generation Immune Checkpoint Inhibitors Market: Johnson and Johnson Sales Forecast, 2022-2035 (USD Million)
Figure 18.3 Next Generation Immune Checkpoint Inhibitors Market: Daiichi Sankyo Sales Forecast, till 2035 (USD Million)
Figure 18.4 Next Generation Immune Checkpoint Inhibitors Market: Arcus Biosciences Sales Forecast, till 2035 (USD Million)
Figure 18.5 Next Generation Immune Checkpoint Inhibitors Market: GlaxoSmithKline Sales Forecast, till 2035 (USD Million)
Figure 18.6 Next Generation Immune Checkpoint Inhibitors Market: Takeda Sales Forecast, till
2035 (USD Million)
Figure 18.7 Next Generation Immune Checkpoint Inhibitors Market: Sanofi Sales Forecast, 2022-2035 (USD Million)
Figure 18.8 Next Generation Immune Checkpoint Inhibitors Market: Regeneron Pharmaceuticals Sales Forecast, till 2035 (USD Million)
Figure 18.9 Next Generation Immune Checkpoint Inhibitors Market: ONO PHARMACEUTICAL Sales Forecast, 2022-2035 (USD Million)
Figure 19.1 Next Generation Immune Checkpoint Inhibitors Market: Darzalex Sales Forecast, 2022-2035 (USD Million)
Figure 19.2 Next Generation Immune Checkpoint Inhibitors Market: Sarclisa Sales Forecast, 2022-2035 (USD Million)
Figure 19.3 Next Generation Immune Checkpoint Inhibitors Market: ONO-4482 Sales Forecast, 2022-2035 (USD Million)
Figure 19.4 Next Generation Immune Checkpoint Inhibitors Market: Ifinatamab Deruxtecan / MK-2400 Sales Forecast, till 2035 (USD Million)
Figure 19.5 Next Generation Immune Checkpoint Inhibitors Market: GSK5764227 Sales Forecast, till 2035 (USD Million)
Figure 19.6 Next Generation Immune Checkpoint Inhibitors Market: Mezagitamab (TAK-079) Sales Forecast, till 2035 (USD Million)
Figure 19.7 Next Generation Immune Checkpoint Inhibitors Market: Domvanalimab Sales Forecast, till 2035 (USD Million)
Figure 19.8 Next Generation Immune Checkpoint Inhibitors Market: Fianlimab Sales Forecast, till 2035 (USD Million)
Figure 19.9 Next Generation Immune Checkpoint Inhibitors Market: Quemliclustat Sakes Forecast, till 2035 (USD Million)
Figure 20.1 Concluding Remarks: Immune Checkpoint Inhibitors Market Landscape
Figure 20.2 Concluding Remarks: Next Generation Immune Checkpoint Inhibitors Market Landscape
Figure 20.3 Concluding Remarks: Clinical Trial Analysis
Figure 20.4 Concluding Remarks: Market Sizing and Opportunity Analysis